1. Home
  2. RYTM vs BNL Comparison

RYTM vs BNL Comparison

Compare RYTM & BNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • BNL
  • Stock Information
  • Founded
  • RYTM 2008
  • BNL 2007
  • Country
  • RYTM United States
  • BNL United States
  • Employees
  • RYTM N/A
  • BNL N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • BNL Real Estate Investment Trusts
  • Sector
  • RYTM Health Care
  • BNL Real Estate
  • Exchange
  • RYTM Nasdaq
  • BNL Nasdaq
  • Market Cap
  • RYTM 3.2B
  • BNL 3.2B
  • IPO Year
  • RYTM 2017
  • BNL 2020
  • Fundamental
  • Price
  • RYTM $57.24
  • BNL $15.07
  • Analyst Decision
  • RYTM Strong Buy
  • BNL Hold
  • Analyst Count
  • RYTM 12
  • BNL 7
  • Target Price
  • RYTM $73.58
  • BNL $18.60
  • AVG Volume (30 Days)
  • RYTM 795.0K
  • BNL 1.8M
  • Earning Date
  • RYTM 05-06-2025
  • BNL 04-30-2025
  • Dividend Yield
  • RYTM N/A
  • BNL 7.58%
  • EPS Growth
  • RYTM N/A
  • BNL 3.57
  • EPS
  • RYTM N/A
  • BNL 0.86
  • Revenue
  • RYTM $130,126,000.00
  • BNL $431,800,000.00
  • Revenue This Year
  • RYTM $45.46
  • BNL $5.31
  • Revenue Next Year
  • RYTM $63.04
  • BNL $4.57
  • P/E Ratio
  • RYTM N/A
  • BNL $17.81
  • Revenue Growth
  • RYTM 68.06
  • BNL N/A
  • 52 Week Low
  • RYTM $35.17
  • BNL $13.96
  • 52 Week High
  • RYTM $68.58
  • BNL $19.15
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 48.62
  • BNL 35.05
  • Support Level
  • RYTM $45.91
  • BNL $13.96
  • Resistance Level
  • RYTM $63.11
  • BNL $17.20
  • Average True Range (ATR)
  • RYTM 3.46
  • BNL 0.55
  • MACD
  • RYTM 0.29
  • BNL -0.25
  • Stochastic Oscillator
  • RYTM 36.33
  • BNL 39.97

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About BNL Broadstone Net Lease Inc.

Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.

Share on Social Networks: